| Identification | Back Directory | [Name]
Delequamine | [CAS]
119905-05-4 | [Synonyms]
RS-42206
Delequamine
RS-15385-197
Delequamine [inn]
(8aR)-3-Methoxy-12-(methylsulfonyl)-5,8,8aα,9,10,11,12,12aα,13,13aα-decahydro-6H-isoquino[2,1-g][1,6]naphthyridine
(8aR)-5,8,8aα,9,10,11,12,12aα,13,13aα-Decahydro-12-(methylsulfonyl)-3-methoxy-6H-isoquino[2,1-g][1,6]naphthyridine
6H-Isoquino[2,1-g][1,6]naphthyridine, 5,8,8a,9,10,11,12,12a,13,13a-decahydro-3-methoxy-12-(methylsulfonyl)-, (8aR,12aS,13aS)- | [Molecular Formula]
C18H26N2O3S | [MOL File]
119905-05-4.mol | [Molecular Weight]
350.48 |
| Hazard Information | Back Directory | [Uses]
Impotence therapy adjunct. | [in vivo]
Delequamine (0.4-6.4 mg/kg; oral, single dose) can increase the sexual behavior score in a dose-dependent manner in a model where untrained male rats are exposed to estrogen-progesterone-treated, sexually receptive female rats. Furthermore, the combination of Delequamine (0.4 mg/kg; oral, single dose) and 8-OH-DPAT (HY-112061) (0.1 mg/kg; subcutaneous injection) can increase the percentage of mounts, intromissions, and ejaculations in rats, shorten the ejaculation latency, and reduce the number of intromissions[1]. | [IC 50]
α2-adrenergic receptor: 9.5 (pKi); α1-adrenergic receptor: 5.3 (pKi) |
|
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|